Safety of Intranasal Irrigation Probiotics in Healthy Volunteers
NCT ID: NCT02933918
Last Updated: 2023-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
36 participants
INTERVENTIONAL
2018-05-17
2019-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A preliminary clinical trial conducted at CHUM Hôtel-Dieu, has allowed us to evaluate the therapeutic potential of intranasal irrigation of probiotics in patients with CRS. This treatment administered twice daily for 14 days was well tolerated and resulted in improved chronic rhinosinusitis symptoms.
Prior to deployment on a larger scale, the safety of this therapy must be confirmed in a healthy population, free of sinus disease. Therefore, this study aims to assess the safety of the use of probiotic intranasal irrigation in healthy volunteers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis
NCT05427695
Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection
NCT04458519
Evolution of the Endonasal Microbiota in Patients With Chronic Rhinosinusitis
NCT04418622
The Use of Prophylactic Antibiotics in Endoscopy Sinus Surgery for Chronic Rhinosinusitis With or Without Polyp
NCT03809312
A Postoperative Study on HVSI vs LVSI Treatment of Chronic Rhinosinusitis
NCT02636959
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will include five (5) periods :
1. Determination of eligibility period (Day 0)
2. Saline irrigation period (Day 0 to Day 7)
3. Elimination of saline period (Day 8 to Day 14)
4. Probiotic treatment period (Day 15 to Day 21)
5. Telephone follow-up period (Day 22 to Day 28)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotics
Probiotics
Safety of nasal irrigation with probiotics in healthy volunteers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotics
Safety of nasal irrigation with probiotics in healthy volunteers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant in general good health.
* Absence of nasal and ear signs or symptoms.
Exclusion Criteria
* Participant with diseases of the middle ear causing impairment of the eardrum or middle ear, or have had surgery of the middle ear previously, except myringotomy with insertion tube.
* Primary or acquired immunodeficiencies documented.
* Antibiotic intake within 30 days before enrollment.
* Unable to do nasal rinse.
* Pregnant woman.
* Smell score from UPSIT-40 under normal smell threshold (\<34).
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Probionase Therapies Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Yvon Desrosiers, MD
Role: STUDY_CHAIR
Probionase Therapies Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PROB001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.